Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Nasal PolypsAsthma, Aspirin-InducedAspirin-Exacerbated Respiratory DiseaseAspirin-Sensitive Asthma With Nasal Polyps

Interventions

DRUG

Dupilumab

8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT05575037 - Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease | Biotech Hunter | Biotech Hunter